Literature DB >> 1330140

Computer system for assisting with clinical interpretation of tumour marker data.

M S Leaning1, S Gallivan, E S Newlands, J Dent, M Brampton, D B Smith, K D Bagshawe.   

Abstract

OBJECTIVE: To design and evaluate a computer advisory system for the treatment of gestational trophoblastic tumour.
DESIGN: A comparison of clinicians' treatment decisions with those of the computer system. Two datasets were used: one to calibrate the system and one to independently evaluate it.
SETTING: Department of medical oncology. PATIENTS: Computerised records of 290 patients with low risk gestational trophoblastic tumour for whom the advisory system could predict the adequacy of treatment. The calibration set comprised patients admitted during 1979-86(227) and the test set patients during 1986-89(63). MAIN OUTCOME MEASURES: The system's accuracy in predicting need to change treatment compared with clinicians' actions. The mean time faster that the system was in predicting the need to change treatment.
RESULTS: On the calibration dataset the system was 94% (164/174) accurate in predicting patients whose treatment was adequate, recommending change when none occurred in only 10 (6%) patients. In patients whose treatment was changed the system recommended change earlier than clinicians in 39/53 cases (74%), with a mean time advantage of 14.9 (SE 2.02) days. On the test dataset the system had an accuracy of 91% (31/34) in predicting treatment adequacy and a false positive rate of 9% (3/34). The system recommended change earlier than clinicians in 22/29 cases (76%), with a mean time advantage of 12.5 (2.22) days.
CONCLUSIONS: The computer advisory system could improve patient management by reducing the time spent receiving ineffective treatment. This has implications for both patient time and clinical costs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330140      PMCID: PMC1883503          DOI: 10.1136/bmj.305.6857.804

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma.

Authors:  R E Hawkins; K Roberts; E Wiltshaw; J Mundy; I J Fryatt; V R McCready
Journal:  Br J Obstet Gynaecol       Date:  1989-12

2.  The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.

Authors:  V J Hunter; L Daly; M Helms; J T Soper; A Berchuck; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1990-10       Impact factor: 8.661

3.  Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.

Authors:  G C Toner; N L Geller; C Tan; J Nisselbaum; G J Bosl
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

4.  The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT).

Authors:  K D Bagshawe; J Dent; E S Newlands; R H Begent; G J Rustin
Journal:  Br J Obstet Gynaecol       Date:  1989-07

5.  Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.

Authors:  M E van der Burg; F B Lammes; W L van Putten; G Stoter
Journal:  Gynecol Oncol       Date:  1988-07       Impact factor: 5.482

6.  Marker half-life analysis as a prognostic tool in testicular cancer.

Authors:  P H Lange; N J Vogelzang; A Goldman; B J Kennedy; E E Fraley
Journal:  J Urol       Date:  1982-10       Impact factor: 7.450

7.  Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.

Authors:  N J Vogelzang; P H Lange; A Goldman; R H Vessela; E E Fraley; B J Kennedy
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

8.  Risk and prognostic factors in trophoblastic neoplasia.

Authors:  K D Bagshawe
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

9.  Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma.

Authors:  V J Picozzi; F S Freiha; J F Hannigan; F M Torti
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

10.  Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.

Authors:  G J Rustin; J N Gennings; A E Nelstrop; H Covarrubias; H E Lambert; K D Bagshawe
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.